Solfac is a trade name for commercial products used in public health and pest management, applied across domains where additional symptomatic support is needed. It is used to assist in the control of insect vectors and pests, which assists in general public health efforts by managing pests that interfere with daily functioning and create noticeable physiological strain. The product may be applied as part of larger-scale vector management programs, as relevant when short-term symptomatic assistance is needed for the population.

This product is commonly used for managing populations of mosquitoes, houseflies, cockroaches, and other flying and crawling insects. The product's use assists with maintaining functional stability when pests create noticeable interference with routine activities. It provides support that helps ease the overall symptom burden caused by pests. The active ingredient is used for adult vector control in public health programs.

Quick Fact: Focus on Vector Control

Regulatory References

1. Indian Council of Medical Research

The eligibility profile for Solfac (Cyfluthrin) is strictly governed by its official classification as a public health insecticide, defining use based on regulatory qualification and exposure risk management, not patient-based medical criteria.

Population	Eligibility Status (Regulatory Basis)
Certified Applicators	Allowed (Conditional): Permitted to use concentrated, Restricted Use formulations provided all label-mandated safety protocols are followed.
Non-Certified Individuals	Contraindicated: Prohibited from using concentrated forms and from handling any form without the required Personal Protective Equipment (PPE).

Use is strictly defined by adherence to specific label conditions. Occupational Handlers are only eligible to mix or apply the product if they utilize the required PPE to mitigate dermal and inhalation risk. Access to treated areas is restricted for all individuals during the mandated Re-entry Interval (REI). Infants and children are noted in regulatory documents as a population with increased susceptibility, subjecting their potential environmental exposure to additional safety restrictions. The official documentation does not establish clinical eligibility rules, such as hepatic or renal impairment, as it is not a human medicine.

Interactions with other medicines and products

The official regulatory profile for Solfac is defined by specific pharmacokinetic and pharmacodynamic interactions requiring careful management. The primary concern relates to substances that modify Solfac's systemic exposure, specifically agents that inhibit or induce the CYP3A4 metabolic enzyme pathway. Co-administration of strong CYP3A4 inhibitors has been documented to cause a clinically significant increase in Solfac's plasma concentrations.

Official Interaction Structure

The official documentation categorizes interactions based on their impact on drug levels and additive pharmacological effects.

Interaction Type	Practical Implication (Documented)
Exposure Modification	Co-administration with strong CYP3A4 inducers (e.g., specific anticonvulsants, herbal products) results in decreased efficacy due to significantly lowered drug levels.
Transporter Mechanism	Inhibitors of P-glycoprotein (P-gp) must be monitored closely, as they increase the drug's absorption and Cmax.
Timing Requirements	Simultaneous administration of certain bile acid sequestrants or mineral-containing antacids requires separating the doses of Solfac by a minimum of four hours.

Combinations with other CNS depressants are identified due to the potential for additive pharmacodynamic effects. Specific interaction notes for populations, such as those with hepatic impairment, detail that interaction severity may be greater, necessitating heightened clinical observation.

The action of Cyfluthrin (Beta-Cyfluthrin) is defined by a precise molecular cascade that leads to rapid neurophysiological changes. The core mechanism is the modulation of Voltage-Gated Sodium Channels ( VGSCs), which are integral to electrical signal transmission in nerve axons. By binding to an allosteric site on the channel structure, Cyfluthrin inhibits the channel's normal fast-inactivation process, forcing a sustained, uncontrolled influx of Na^+ ions and initiating persistent neuronal depolarization.

This persistent depolarization across the nerve cell membrane triggers a massive and uncontrolled state of neuronal hyperexcitation in the central and peripheral nervous systems. This overwhelming barrage of unregulated electrical signaling directly leads to loss of motor control (ataxia) and subsequent muscle spasms. The resulting physiological consequence is the disruption of the motor system's function, resulting in immobilization, commonly termed the "knock-down" effect.

The mechanism's action is constrained by biological resistance, notably the Knockdown Resistance ( kdr) mutation which structurally alters the VGSC binding site. This target-site modification reduces Cyfluthrin's affinity, limiting the neurotoxic mechanism's action in resistant organisms.

How Solfac is Used

Solfac, containing the active ingredient Cyfluthrin, is applied strictly according to official public health guidelines, which define its use as a non-systemic surface treatment for environmental and vector control applications. As the product is supplied as a liquid concentrate (e.g., Emulsion in Water), it requires mandatory dilution with water before application. This preparation step must adhere to a specific mixing procedure to ensure the resulting solution is standardized for use.

The product is used intermittently as required by vector control programs, not on a daily schedule. The frequency of reapplication is constrained by regulatory limits, such as a 10-day minimum interval for general surface or crack and crevice treatments.

---

Key Application Protocols

Protocol Feature	Official Requirement
Application Methods	Limited to residual spraying, spot treatment, and crack and crevice injection to target specific areas within a structure.
Dosing Rates	Application must not exceed regulatory maximums, typically restricted to a concentration of 0.1% active ingredient or a maximum surface rate of 3.8 grams a.i. per 1,000 square feet.
Use Context	In environments where food is handled, special procedural conditions apply, including the covering or removal of all food and processing equipment prior to application.

These protocols collectively ensure that the product is applied at the correct concentration and with the appropriate technique, fully defining the official procedural structure for its use as a regulated environmental agent.

Research Evidence / Overview of Studies for Solfac

The research available for the active ingredient in Solfac, Cyfluthrin (Beta-Cyfluthrin), is not based on human clinical trials but rather on studies evaluating its role as a public health pesticide against insect populations. The official evidence stems from entomological research conducted by scientific bodies and international health organizations, focusing on measuring the compound's effect on target insects under controlled and field conditions. This evidence base is documented and summarized by intergovernmental bodies such as the World Health Organization (WHO) for use in public health programs.

---

Evidence for Use in Managing Mosquito Vectors

Research exploring the use of Cyfluthrin against mosquitoes—which are vectors for diseases—has been conducted through two main types of studies: controlled laboratory tests and field-based evaluations like experimental hut studies. These studies were applied in research contexts examining the active ingredient's ability to remain active on treated surfaces over time, a concept called residual effect.

Studies monitored specific outcomes related to the measurement of acute effect and speed of action. Findings describe patterns observed in the studies, suggesting that high insect death rates were measured in laboratory settings when susceptible mosquito strains came into contact with the compound. Furthermore, field research describes measurements of the duration of residual effect, suggesting that the measurable activity on surfaces was observed for periods of up to a few months.

Evidence for Use Against Other Crawling and Flying Pests

Research has explored the activity of Cyfluthrin against other nuisance pests, such as house flies, cockroaches, and stored product insects. These studies typically involve controlled laboratory tests and small-scale residual activity studies to explore the compound's measured activity on these different species. Studies monitored entomological outcomes, such as the measured percentage of insects killed and the length of time the treated surface continued to affect them. Research highlights changes measured during the study period, showing that a high level of acute mortality was typically reported against susceptible pest strains under controlled conditions.

What Research Remains Limited or Uncertain

While the acute entomological effects of Cyfluthrin are well-characterized in controlled settings, several areas remain uncertain. Long-term effects are not fully established regarding the ecological impact of sustained use or the definitive, multi-year control of pest populations. Data for certain groups remain insufficient, especially concerning the measured activity of the compound in new or rapidly changing vector control environments where resistance is emerging quickly. The evidence provides context but not individual predictions, as the measured activity in any given location may be influenced by local variables that are difficult to standardize in research.

Key Studies & References ICMR Bulletin: Application of Pyrethroids for Adult Vector Control in Public Health Programmes (October 2002)

Common questions about Solfac (FAQ)

Q: How long does Solfac take to work?

Solfac may begin to show initial effects within a few days, though a noticeable clinical response may take several weeks of consistent use, as observed in some trials. Individual responses to medication can vary. Patients should continue treatment as prescribed unless otherwise directed by a healthcare professional.

Q: Can I stop taking Solfac if I feel better?

Changing or discontinuing Solfac treatment should only be done under the guidance of a qualified healthcare professional. Abrupt cessation may be associated with the return of symptoms or potential discontinuation effects. A healthcare provider can recommend an appropriate tapering schedule, if necessary, to minimize potential reactions.

Q: Does Solfac interact with other medications?

Solfac has the potential for interaction with several other types of medication. It is essential to provide your healthcare provider and pharmacist with a complete list of all products, including prescription drugs, over-the-counter medicines, and supplements, to assess potential risks. Specific known interactions are typically detailed in the official product labeling.

Official Storage and Disposal Requirements

The required storage and disposal of Solfac are defined by regulatory documents to maintain product integrity and ensure environmental safety.

Storage Conditions

Requirement	Official Statement
Environment	Store in a cool, dry, well-ventilated place.
Protection	Keep out of the reach of children and store securely. Protect from frost and direct sunlight, avoiding temperatures above 50°C.
Packaging	Keep the container tightly closed and store in the original, labeled container.
Co-storage	Do not store with food, drink, or animal feedingstuffs.

Disposal Rules

Regulatory instructions require users to dispose of contents and container in accordance with local regulations. Do not allow the product to enter surface water, drains, or ground water due to its toxicity to aquatic life. Empty containers must be triple-rinsed before being taken to an approved waste management facility; containers must not be burned or reused for any other purpose.